Data on the overdose of the drug is not provided.
hypersensitivity,
severe hepatic insufficiency,
severe renal failure,
parkinsonism,
pregnancy,
lactation period,
children under 5 years of age.
With caution:
Parkinson's disease,
renal and / or hepatic insufficiency.
Combarel® increases the effects of drugs, CNS depressants, ethanol, as well as nootropic and antihypertensive agents.
Improves the tolerance of antipsychotic drugs (neuroleptics) and tricyclic antidepressants.
Vasodilating drugs enhance the effect of Combitropil®.
Gelatin capsules, size No. 0, white, the contents of the capsules are white or almost white powder.
From the central nervous system and peripheral nervous system: irritability, sleep disturbance, headache, tremor of the extremities.
From the digestive system: dyspepsia, epigastric pain, dry mouth.
Allergic reactions: skin rash.
During treatment, liver function should be monitored.
At the beginning of treatment, the patient should refrain from taking alcohol.
Due to the content of cinnarizine, the drug can cause a positive reaction when conducting a doping test in athletes.
The drug should be used with caution in cases of increased intraocular pressure.
Influence on the ability to drive vehicles and manage mechanisms
During the treatment period, care should be taken when driving a car and engaging in activities that require increased concentration and speed of psychomotor reactions.
disorders of cerebral circulation (including atherosclerosis of the cerebral vessels, ischemic stroke, during the post-treatment period after hemorrhagic stroke, after TBI),
encephalopathies of various origins,
and subcomittee comatose state after intoxication and injury of the brain,
diseases of the central nervous system, accompanied by a decrease in intellectual and mnestic functions,
labirintovaya of different Genesis (accompanied by dizziness, tinnitus, nystagmus, nausea and vomiting), Meniere's syndrome,
depression,
psycho-organic syndrome with prevalence of signs of fatigue and weakness,
asthenia of psychogenic origin,
prevention of migraines and kinetoses,
impaired memory, mental function, and concentration,
backlog of intellectual development in children.
It has a pronounced antihypoxic (mutually potentiated components), nootropic and vasodilating effect. Promotes a significant increase in blood flow in the brain.
Piracetam - nootropic agent. It has a positive effect on the metabolic processes of the brain: increases the concentration of ATP in the brain tissue, increases the synthesis of RNA and phospholipids, stimulates glycolytic processes, increases the utilization of glucose.
It improves the integrative activity of the brain, promotes memory consolidation, and facilitates the learning process.
Changes the rate of propagation of arousal in the brain, improves microcirculation, without having a vasodilating effect, suppresses the aggregation of activated platelets.
It has a protective effect on brain damage caused by hypoxia, intoxication, electric shock, increases α - and β-activity, reduces δ-activity on the EEG, reduces the severity of vestibular nystagmus.
Improves interneuronal transmission and synaptic conduction in neocortical structures, increases mental performance, improves brain blood flow.
The effect develops gradually. Almost does not have a sedative and stimulating effect.
The therapeutic effect of piracetam is manifested in 1-6 hours.
Cinnarizine - selective BCC, reduces the intake of calcium ions into the cells and reduces its content in the depot of the plasmolemma, reduces the tone of the smooth muscles of the arterioles, reduces their reaction to biogenic vasoconstrictors (including epinephrine, norepinephrine, dopamine, angiotensin, vasopressin, serotonin).
It has a vasodilating effect (especially in relation to the blood vessels of the brain, increasing the antihypoxic effect of piracetam), does not significantly affect blood pressure.
It shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system.
In patients with peripheral circulatory disorders, it improves blood supply to organs and tissues (including the myocardium), increases postischemic vasodilation.
Increases the elasticity of the membranes of red blood cells, their ability to deform, reduces the viscosity of the blood.
The toxicity of the combination does not exceed the toxicity of the individual components of the drug.
The drug is quickly and completely absorbed from the gastrointestinal tract.
Piracetam
Suction
The bioavailability of piracetam is 95%. Cmax piracetam is reached in 2-6 hours.
Distribution
Piracetam does not bind to plasma proteins. Penetrates through the BBB, the placental barrier. It accumulates in the brain tissue 1-4 hours after ingestion. It is removed from the cerebrospinal fluid much more slowly than from other tissues.
Metabolism and excretion
Piracetam is practically not metabolized. T1/2 piracetam from blood plasma-4.5 h, T1/2 from the brain-an average of 7.7 hours. It is mainly excreted by the kidneys (more than 95% of the dose taken in 30 hours).
Cinnarizine
Suction
Withmax cinnarizine is reached in 1-4 hours.
Distribution
Cmax cinnarizine after 1-4 hours is noted not only in the blood, but also in the liver, kidneys, heart, lungs, spleen and brain. Binding to plasma proteins — 91%.
Metabolism and excretion
Cinnarizine is completely metabolized in the liver (by disalkylation). T1/2 cinnarizine — 4 hours. It is excreted as metabolites (1/3-by the kidneys with urine, 2/3-through the intestine with feces).
In a place protected from light, at a temperature not exceeding 25 °C.
Keep out of reach of children.
The shelf life of the drug Combarel®3 года.Do not use after the expiration date indicated on the package.
| Capsules | 1 caps. |
| piracetam | 400 mg |
| cinnarizine | 25 mg |
| excipients: MCC, lactose (milk sugar), magnesium stearate, talc | |
| shell: titanium dioxide, methyl parahydroxybenzoate, propyl parahydroxybenzoate, acetic acid, gelatin |
in a contour cell package of 10 pcs. , in a pack of cardboard 3 or 6 packages, or in polymer cans of 20 or 60 pcs., in a pack of cardboard 1 bank.
Contraindicated in pregnancy. Breastfeeding should be discontinued for the duration of treatment.
Inside.
Adults-1-2 caps. 3 times a day for 1-3 months, depending on the severity of the disease.
Children over the age of 5 years — 1-2 caps. 1-2 times a day for 1-3 months.
Courses of treatment are carried out 2-3 times a year.
In chronic renal failure (creatinine Cl <60 ml / min), it is necessary to reduce the dose or increase the interval between doses of the drug.
N06BX Other psychostimulants and nootropic drugs
